Gelomics is proud to announce the award of $948,066 in non-dilutive grant funding through the Industry Growth Program under the Commercialisation and Growth stream. The $1.9 million project will fast-track the commercialisation of Gelomics’ next-generation AI-assisted 3D Tissue Culture Platform, which provides a predictive and ethical alternative to traditional drug development models. Gelomics extends its sincere thanks to the Industry Growth Program for supporting this important work.
“The Industry Growth Program is a game-changer for Gelomics. This funding will accelerate our journey toward transforming drug development by replacing outdated and unreliable models with human-relevant testing solutions. We are excited to lead the next generation of biotechnology innovation.”
– Dr. Christoph Meinert, CEO of Gelomics